Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. If you miss a scheduled appointment for a dose of this medicine, contact your doctor immediately for further instructions.
Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
Leflunomide (severe)
Live vaccines (severe)
Etanercept (severe)
Doxorubicin (severe)
Ganciclovir (moderate)
Adalimumab (severe)
Paclitaxel (moderate)
Warfarin (moderate)
Baricitinib (severe)
This medicine is indicated for the treatment of early-stage breast cancer that is human epidermal growth factor receptor-2 positive (HER2+) and has spread to the lymph nodes. It is also used for the treatment of HER2+ cancer that has not spread to the lymph nodes and is estrogen receptor/progesterone receptor negative or with one high-risk feature. This medicine is used either alone or in a combination with other anticancer therapies.
This medicine is indicated for the treatment of metastatic breast cancer that is human epidermal growth factor receptor-2 positive (HER2+). It is used either alone or in a combination with other anticancer therapies.
This medicine is indicated for the treatment of metastatic cancer of the stomach or the gastroesophageal junction that is human epidermal growth factor receptor-2 positive (HER2+). It is used in a combination with other anticancer therapies in patients who have not received any prior treatment for the metastatic disease.
Fever
Headache
Nausea and Vomiting
Tiredness and weakness
Shortness of breath
Diarrhea
Reduction in blood cell count (severe)
Infections (severe)
Muscle and joint pain
Increased
Swelling of mucous membranes
Swelling of the face, lips, or tongue (severe)
Change in taste
Sleep disturbances
Stomach pain
Heartburn and indigestion
Depression (severe)
Unusual bleeding or bruising (severe)
Pale skin (severe)
This medicine is not recommended for use in patients with a known allergy to Kadcyla Infusion 100 mg 1 Vial or any other inactive ingredients present along with it.